IMRX

3.3802.03%
TJ

Thomas J. Schall

Chairman of the Board

Dr. Thomas J. Schall, also known as Tom, Ph.D. is Director of Immuneering Corporation from March 2024 and serves as its Chairman of the Board from September 2025. He founded ChemoCentryx Inc. in November 1996 and had been its Chief Executive Officer, President and Director since 1997 until October 20, 2022. Dr. Schall focuses on the discovery and development of chemokine-based therapeutics widely regarded as a Leader in chemokine research, his laboratories have been responsible for the discovery or co-discovery of almost one-third of all known chemokine receptors. From December 1993 to November 1996, he worked at the DNAX ResearchInstitute, a division of Schering-Plough Corporation, a pharmaceutical company. Prior to DNAX, Dr. Schall served as a Scientist of Genentech Inc. He has published approximately 100 articles in noted peer-reviewed journals, including Cell, Nature, Science and the Journal of Immunology. Dr. Schall had been the Chairman of the Board of ChemoCentryx, Inc. since April 2012 until October 20, 2022. He received his B.S. in biology from Northern Illinois University. Dr. Schall received his Ph.D. in Cancer Biology from Stanford University.

Positions